Disclosed are novel A.sub.2B adenosine receptor antagonists having the
structure of Formula I or Formula II: 1
The compounds are particularly useful for treating asthma, inflammatory
gastrointestinal tract disorders, cardiovascular diseases, neurological
disorders, and diseases related to undesirable angiogenesis.
